Zentalis Pharmaceuticals (ZNTL) Retained Earnings (2019 - 2026)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Retained Earnings of -$1.2 billion for Q1 2026, down 187.78% year-over-year from $1.4 billion in Q1 2025, and down 626021.94% quarter-over-quarter from $196000.0 in Q4 2025.
Zentalis Pharmaceuticals (ZNTL) Retained Earnings (2019 - 2026) Analysis & Trends
Zentalis Pharmaceuticals' Retained Earnings history runs 8 years deep, the most recent figure standing at -$1.2 billion for Q1 2026.
- In Q1 2026, Retained Earnings fell 187.78% year-over-year to -$1.2 billion; the TTM figure through Mar 2026 stood at -$1.2 billion (down 187.78% YoY), while the FY2025 annual figure was $196000.0, up 100.02% from the prior year.
- Retained Earnings for Q1 2026 stood at -$1.2 billion, down from $196000.0 in the prior quarter.
- The five-year high for Retained Earnings was $1.4 billion in Q1 2025, with the low at -$1.2 billion in Q1 2026.
- The 5-year median for Retained Earnings is -$1.4 million (2022), against an average of -$149.3 million.
- The sharpest annual moves came in 2022 and 2024: Retained Earnings surged 1469894.0% in 2022, then tumbled 157901.44% in 2024.
- Zentalis Pharmaceuticals' Retained Earnings stood at -$1.4 million in 2022, then sank by 65573.02% to -$888.6 million in 2023, then dropped by 18.66% to -$1.1 billion in 2024, then soared by 100.02% to $196000.0 in 2025, then tumbled by 626021.94% to -$1.2 billion in 2026.
- Business Quant data shows ZNTL's Retained Earnings at -$1.2 billion in Q1 2026, $196000.0 in Q4 2025, and -$1.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Zentalis Pharmaceuticals | 255.14 Mn | 255.14 Mn | - | 1.41 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.41 Bn |
| Mar 31, 2026 | -1.23 Bn |
| Dec 31, 2025 | 196,000.00 |
| Sep 30, 2025 | -1.16 Bn |
| Jun 30, 2025 | 59,000.00 |
| Mar 31, 2025 | 1.40 Bn |
| Dec 31, 2024 | -1.05 Bn |
| Sep 30, 2024 | 1.59 Mn |
| Jun 30, 2024 | 140,000.00 |
| Mar 31, 2024 | -878.49 Mn |
| Dec 31, 2023 | -888.56 Mn |
| Sep 30, 2023 | 1.31 Bn |
| Jun 30, 2023 | -772.11 Mn |
| Mar 31, 2023 | -556,000.00 |
| Dec 31, 2022 | -1.35 Mn |
| Sep 30, 2022 | -2.27 Mn |
| Jun 30, 2022 | -1.78 Mn |
| Mar 31, 2022 | 735.00 Mn |
| Dec 31, 2021 | -125,000.00 |
| Sep 30, 2021 | 702.86 Mn |